Kuantum Papers Unveils ₹735 Cr Expansion Amidst Margin Pressure

Kuantum Papers Ltd. has outlined its strategic roadmap, detailing a substantial ₹735 crore capital expenditure plan alongside 9-month FY26 operational revenues of ₹792.2 crore.
The investor presentation also revealed a PAT margin of 3.49% for the same period, highlighting the challenges faced even as the company gears for significant growth.

Reader Takeaway: CapEx plans signal growth potential; declining revenue and margins pose short-term challenges.

What just happened (today’s filing)

Kuantum Papers Limited presented its investor deck on February 25, 2026, outlining significant future growth strategies and current operational performance.

The company reported 9-month FY26 operational revenues of ₹7,922 million (₹792.2 crore), with an EBITDA margin of 14.39% and a Profit After Tax (PAT) margin of 3.49%.

FY25 saw paper sales volume reach 1,60,845 metric tonnes (MT), with current operating capacity at 500 TPD.
A planned capital expenditure of ₹7,350 million (₹735 crore) is earmarked for modernization and expansion.

Why this matters

The planned expansion aims to increase production capacity by approximately 50%, a move crucial for capturing market share in a growing paper industry.

Kuantum Papers is also strategically positioning itself to leverage the single-use plastic ban by developing specialty and eco-friendly paper products.

Adoption of Industry 4.0 technologies is intended to enhance operational efficiency and resource management, potentially improving cost structures.

The backstory (grounded)

Kuantum Papers is undertaking a substantial ~₹735 crore (₹7,350 million) expansion project spread over FY24-FY26, focusing on plant modernization and capacity enhancement.
This expansion aims to significantly increase production capacity from approximately 450 TPD to 675 TPD, alongside upgrading machinery and adding specialty grade capacity.

Recent quarters, such as Q1 FY26, saw a significant year-on-year decline in revenue, EBITDA, and net profit. This was primarily attributed to planned, temporary shutdowns of paper machines for crucial upgrades.

The company is actively focusing on developing specialty paper products, aiming to capitalize on the ongoing ban on single-use plastics, and is exploring the tissue paper segment to diversify its portfolio.

Kuantum Papers also withdrew its ratings from CARE Ratings and subsequently switched to India Ratings and Research, signalling a shift in its financial assessment approach.

What changes now

Shareholders can expect a significant increase in the company's production capacity, targeting around 675 TPD from the current ~450-500 TPD.
The company's product portfolio is set to diversify with a greater emphasis on specialty and potentially tissue paper segments.

Implementation of Industry 4.0 technologies is expected to streamline operations and optimize resource utilization, potentially leading to better cost management.

The substantial capital expenditure indicates a strong commitment to modernization and future growth, aiming to improve cost structures and competitiveness.

Risks to watch

MarketsMojo has issued a 'Strong Sell' rating, citing persistent negative earnings for eight consecutive quarters and a low Return on Capital Employed (ROCE) of 7.02%.

There are inherent project implementation and stabilization risks associated with the large ₹735 crore capital expenditure plan.

The paper industry is highly competitive, with companies facing challenges from raw material price volatility and import pressures, which can affect profitability.

Planned operational shutdowns for upgrades, as seen in Q1 FY26, can lead to short-term declines in revenue and profits.

Peer comparison

Kuantum Papers operates in an industry populated by major players like JK Paper Ltd., ITC Limited – Paperboards & Specialty Papers Division, West Coast Paper Mills Ltd, and Tamil Nadu Newsprint and Papers Limited (TNPL).

The Indian paper market is projected for robust growth, estimated at around 9.8% CAGR through 2031, fueled by demand in packaging and specialty paper segments.

However, intense competition and volatility in raw material prices remain significant industry-wide challenges that all players must navigate.

Context metrics (time-bound)

• Operational Income has shown a declining trend: ₹13,096 million (FY23), ₹12,113 million (FY24), ₹11,070 million (FY25), and ₹7,922 million (9M-FY26) [Consolidated].
• EBITDA Margins have contracted: 28.96% (FY23), 27.49% (FY24), 21.92% (FY25), and 14.39% (9M-FY26) [Consolidated].
• PAT Margins have also reduced: 10.40% (FY23), 15.17% (FY24), 10.41% (FY25), and 3.49% (9M-FY26) [Consolidated].
• The company has approved a capital expenditure of ₹7,350 million for its expansion plans between FY24-FY26 [Not specified].

What to track next

Monitor the execution progress and timeline of the ₹735 crore expansion project, including capacity ramp-up milestones.
Track the market adoption and financial performance of new specialty and tissue paper product lines.
Evaluate the company's ability to improve cost structures and margins through operational efficiencies and Industry 4.0 implementation.
Observe future quarterly results for signs of sustained revenue growth and profitability recovery.
Assess the company's competitive positioning against peers as new capacities come online.